Usca Ria LLC boosted its position in Pfizer, Inc. (NYSE:PFE) by 19.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 331,931 shares of the biopharmaceutical company’s stock after buying an additional 54,492 shares during the period. Pfizer comprises approximately 1.7% of Usca Ria LLC’s holdings, making the stock its 6th largest position. Usca Ria LLC’s holdings in Pfizer were worth $11,355,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in PFE. Naples Global Advisors LLC increased its position in shares of Pfizer by 0.3% in the first quarter. Naples Global Advisors LLC now owns 24,552 shares of the biopharmaceutical company’s stock worth $840,000 after buying an additional 79 shares in the last quarter. Pure Financial Advisors Inc. increased its position in Pfizer by 0.4% in the first quarter. Pure Financial Advisors Inc. now owns 22,091 shares of the biopharmaceutical company’s stock valued at $756,000 after buying an additional 84 shares during the period. Alpha Windward LLC increased its position in Pfizer by 1.1% in the first quarter. Alpha Windward LLC now owns 8,387 shares of the biopharmaceutical company’s stock valued at $287,000 after buying an additional 89 shares during the period. Peachtree Investment Advisors Inc. increased its position in Pfizer by 1.3% in the first quarter. Peachtree Investment Advisors Inc. now owns 7,516 shares of the biopharmaceutical company’s stock valued at $257,000 after buying an additional 100 shares during the period. Finally, Acropolis Investment Management LLC increased its position in Pfizer by 1.9% in the first quarter. Acropolis Investment Management LLC now owns 5,251 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 100 shares during the period. Institutional investors and hedge funds own 69.94% of the company’s stock.

Pfizer, Inc. (PFE) traded up 0.48% during midday trading on Friday, reaching $33.39. The company’s stock had a trading volume of 14,393,883 shares. Pfizer, Inc. has a 12-month low of $29.83 and a 12-month high of $35.18. The stock has a market cap of $198.58 billion, a P/E ratio of 24.43 and a beta of 1.00. The stock’s 50 day moving average is $33.25 and its 200 day moving average is $33.42.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The firm had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same period last year, the firm earned $0.64 EPS. The firm’s revenue was down 1.9% compared to the same quarter last year. Analysts anticipate that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 3.83%. The ex-dividend date of this dividend is Wednesday, August 2nd. Pfizer’s dividend payout ratio is currently 94.12%.

COPYRIGHT VIOLATION WARNING: This article was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/08/26/pfizer-inc-pfe-shares-bought-by-usca-ria-llc.html.

PFE has been the topic of several recent analyst reports. Sanford C. Bernstein set a $39.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Monday, July 17th. Cowen and Company set a $43.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Monday, July 10th. Barclays PLC restated a “buy” rating and set a $38.00 price objective on shares of Pfizer in a report on Wednesday, May 3rd. UBS AG restated a “buy” rating and set a $38.00 price objective on shares of Pfizer in a report on Monday, July 31st. Finally, ValuEngine downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $37.61.

In related news, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the sale, the insider now directly owns 151,474 shares in the company, valued at approximately $5,074,379. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Laurie J. Olson sold 8,064 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $32.70, for a total value of $263,692.80. Following the completion of the sale, the insider now owns 74,506 shares in the company, valued at $2,436,346.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 120,014 shares of company stock worth $4,062,493. 0.06% of the stock is owned by insiders.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.